CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union

CAMP4 received approval under the EU Clinical Trials Regulation to initiate its global Phase 1/2 trial of CMP-002. The clearance follows recent approvals in the United Kingdom, Australia, and Argentina; the article provides no trial results or financial figures.